Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Bozkurt B … Kaplan LM Journal: The Lancet Published: 2026-11-09 DOI: https://doi.org/10.1016/S0140-6736(26)02140-9